英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字，中文词皆可：


请选择你想看的字典辞典：
单词字典翻译
tiddly查看　tiddly　在百度字典中的解释百度英翻中〔查看〕
tiddly查看　tiddly　在Google字典中的解释Google英翻中〔查看〕
tiddly查看　tiddly　在Yahoo字典中的解释Yahoo英翻中〔查看〕

安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
    TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
  • FDA Approves Tislelizumab Plus Chemo for PD-L1+ Unresectable or . . .
    Key Takeaways Tislelizumab-jsgr (Tevimbra) approved for first-line treatment of HER2-negative gastric or GEJ adenocarcinoma with PD-L1 expression Phase 3 RATIONALE-305 trial showed significant
  • TEVIMBRA Approved in U. S. for First-line Treatment of Gastric and . . .
    “Today’s FDA approval of TEVIMBRA for the treatment of gastric or gastroesophageal junction cancers in PD-L1 positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” said Mark Lanasa, M D , Ph D , Chief Medical Officer, Solid Tumors at BeiGene “This is the second U S approval for TEVIMBRA this year
  • FDA Approves Tislelizumab in Combination With Chemotherapy for Gastric . . .
    “ [The] FDA approval of Tevimbra for the treatment of gastric or gastroesophageal junction cancers in PD-L1–positive adult patients marks a significant step forward in our mission to deliver transformative therapies to patients with cancer,” Mark Lanasa, MD, PhD, chief medical officer of solid tumors at BeiGene, said in a news release
  • FDA Approves Tislelizumab-jsgr (Tevimbra) Combo for Gastric or . . .
    The U S Food and Drug Administration approved tislelizumab-jsgr (Tevimbra) in combination with chemotherapy as a first-line treatment for adults with unresectable or metastatic HER2-negative gastric or gastroesophageal junction adenocarcinomas whose tumors express PD-L1
  • FDA Approves Tevimbra as First-Line Treatment for Gastric Cancers | medtigo
    Tevimbra is FDA-approved as a first-line therapy for HER2-negative gastric and GEJ cancers, offering a breakthrough treatment option for patients
  • September 26, 2024 Meeting of the Oncologic Drugs Advisory Committee . . .
    Considering the poor prognosis and the limited availability of effective treatment choices in the first-line setting in the past decades for advanced or metastatic G GEJ cancer, there is still a
  • FDA Approves Tevimbra Combination for Gastric or Gastroesophageal . . .
    A drug called Tevimbra (tislelizumab-jsgr) has been approved for use with chemotherapy as first-line treatment of PD-L1 positive unresectable or metastatic HER2-negative gastric or gastroesophageal junction (GEJ) adenocarcinoma Tevimbra was approved earlier in 2024 to treat unresectable or metastatic esophageal squamous cell carcinoma
  • FDA Approves BeiGene’s Tevimbra for Unresectable or Metastatic HER2 . . .
    The FDA has approved BeiGene’s Tevimbra (tislelizumab-jsgr) in combination with platinum and fluoropyrimidine-based chemotherapy for the first-line treatment of unresectable or metastatic HER2-negative gastric or gastroesophageal junction (G GEJ) adenocarcinoma in adults with PD-L1 expression The approval, which was the second for Tevimbra in 2024, is supported by results from the RATIONALE
  • TEVIMBRA Received FDA Approval as First-Line Therapy for Gastric and . . .
    The prognosis for patients with gastric or GEJ cancer depends on the stage at diagnosis, treatment response, and overall health Immunotherapies, such as TEVIMBRA (tislelizumab), offer a promising approach for first-line treatment in patients with PD-L1 positive advanced or metastatic gastric and GEJ cancers





中文字典-英文字典  2005-2009